



Flarin Holdings completes oversubscribed second round of fundraising to drive rapid commercialisation of world's first lipid formulated ibuprofen

Flarin Holdings Limited (FHL), trading under the name Infirst Limited, today announces the completion of its second fund-raising round.

Following its initial investment in 2019, IW Capital again led the funding to support the exciting development of this fast-growing business. Over the past year Flarin has seen expansion through sales of Flarin Joint and Muscular Pain Relief into mass multiples such as Boots, Superdrug, Sainsbury, Morrisons as well as Amazon, Ocado and other online retailers.

Flarin Holdings was originally demerged from a group, Infirst Healthcare Limited, in 2019 in order to provide greater focus on the rapid commercialisation of Flarin. IW Capital provided the initial growth capital to support the management and the business plan in a first round in October 2019.

Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain 1 . Flarin's unique lipid formulation also helps to shield the stomach from damage 2 .

Luke Davis, CEO of IW Capital, commented on the investment: "We are hugely excited to be involved with this innovative pharmaceutical product at an early stage in its commercial development. The first round of funding was a huge success and this one, being oversubscribed, has mirrored that. In the current climate, Flarin is in a superb position to expand its UK market share and expand into overseas markets.

"It is also key to be able to work with such an experienced management team in the pharmaceutical and healthcare arena. There is a fantastic exit opportunity here with the product already fully developed and on sale in UK pharmacies and supermarkets. We look forward to supporting the future growth of Flarin in the coming years."

"It gives us great confidence to have attracted this oversubscribed funding round during lockdown and at an increased valuation. We look forward to taking Flarin to the next stage of its commercial development," said Andrew Macmillen, Managing Director. "These new funds give Flarin greater ability to increase investment in marketing in the UK as well as continuing to progress regulatory submissions and partnerships in other countries."



About Flarin Holdings

Flarin Holdings was demerged from Infirst Healthcare Limited in 2019 in order to focus on commercialising Flarin's unique lipid formulation of ibuprofen.

About Flarin Lipid Formulation Technology

Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain 1 . Flarin's unique lipid formulation also helps to shield the stomach from damage 2 .

About IW Capital

IW Capital is a leading private equity house which has provided over c.£100m in development capital investment to UK companies.

Media enquiries:

andrew.macmillen@infirst.co.uk	+44 (0) 207 153 6600
mary.ohagan@infirst.co.uk	+44 (0) 207 153 6600
tariq@iwcapital.co.uk	+44 (0) 207 015 2250

References

1 Bierma- Zeinstra SMA, Conaghan PG, Brew J et al. Osteoarthr Cartil: 2017 25; 12: 1942–1951
Open Access: <http://dx.doi.org/10.1016/j.joca.2017.09.002> Accessed at:
[http://www.oarsijournal.com/article/S1063-4584\(17\)31197-4/fulltext](http://www.oarsijournal.com/article/S1063-4584(17)31197-4/fulltext)
2 Data on file, Infirst Healthcare Limited. www.flarin.co.uk
<https://www.linkedin.com/company/flarin/>